BioTelemetry's gross profit for the
three
months ended in Sep. 2020 was $69.0 Mil. BioTelemetry's gross profit for the trailing twelve months (TTM) ended in Sep. 2020 was $270.9 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. BioTelemetry's gross profit for the
three
months ended in Sep. 2020 was $69.0 Mil. BioTelemetry's Revenue for the
three
months ended in Sep. 2020 was $114.7 Mil. Therefore, BioTelemetry's Gross Margin % for the quarter that ended in Sep. 2020 was 60.17%.
BioTelemetry had a gross margin of 60.17% for the quarter that ended in Sep. 2020 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of BioTelemetry was 62.70%. The lowest was 56.11%. And the median was 60.26%.
BioTelemetry Gross Profit Historical Data
The historical data trend for BioTelemetry's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioTelemetry's Gross Profit
For the Diagnostics & Research subindustry, BioTelemetry's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioTelemetry's Gross Profit Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BioTelemetry's Gross Profit distribution charts can be found below:
* The bar in red indicates where BioTelemetry's Gross Profit falls into.
BioTelemetry Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
BioTelemetry's Gross Profit for the fiscal year that ended in Dec. 2019 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $270.9 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BioTelemetry (NAS:BEAT) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BioTelemetry had a gross margin of 60.17% for the quarter that ended in Sep. 2020 => Durable competitive advantage
BioTelemetry Gross Profit Related Terms
Thank you for viewing the detailed overview of BioTelemetry's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
BioTelemetry Inc provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. It operates under healthcare, technology, and research segments. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials and the Technology segment, focuses on the development, manufacturing, testing, and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BEAT has been successfully added to your 